NEW YORK (GenomeWeb News) – Horizon Discovery announced on its website today that it has inked a collaborative agreement with Janssen Pharmaceutica division Ortho Biotech Oncology Research & Development.

Cambridge, UK-based Horizon said that the deal covers the licensing of certain of its X-MAN cell lines including major cancer-causing genes and their matched normal genetic backgrounds. Horizon said that the cell lines could help the J&J unit to gather information related to selectivity and mode of action of drug candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.

The New York Times' George Johnson muses on cancer's roots in multicellularity.